Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Drug Discovery 8, 846–847 (1 November 2009) | doi:10.1038/nrd3035
HIV: A new starting point for HIV vaccine design
Abstract
Identifying broadly neutralizing antibodies (BNAbs) against HIV, which recognize most manifestations of this highly mutable virus, is important in achieving the elusive goal of developing a viable HIV vaccine. However, although the BNAbs that have been identified are effective in primate models of HIV, they show limited potency against non-clade B viruses, which are responsible for most HIV infections outside Europe and North America.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
